Adaptive Benzathine Analogs for High-Risk Environments

Publication ID: 24-11857550_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Adaptive Benzathine Analogs for High-Risk Environments,” Published Technical Disclosure No. 24-11857550_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857550_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,550.

Summary of the Inventive Concept

This inventive concept adapts benzathine analogs for treating inflammatory disorders in high-risk environments, such as emergency response situations, high-altitude areas, remote disaster-relief settings, and extreme weather conditions.

Background and Problem Solved

The original patent disclosed benzathine analogs for treating inflammatory disorders. However, these analogs may not be effective or practical in high-risk environments, where unique challenges and constraints exist. This inventive concept addresses the limitations of the original patent by adapting the benzathine analogs for these specific contexts.

Detailed Description of the Inventive Concept

The new inventive concept comprises specialized variations of benzathine analogs, designed to operate effectively in high-risk environments. For example, a portable, waterproof device can administer the compound in emergency response situations. In high-altitude environments, the compound can be formulated to maintain potency despite lower atmospheric pressure. In remote disaster-relief settings, a kit with a manual for administering the compound in low-resource environments can be provided. Additionally, the composition can be stabilized to maintain potency in extreme temperatures, and a wearable, temperature-controlled device can monitor vital signs and adjust the dosage accordingly.

Novelty and Inventive Step

The new claims introduce novel features, such as portability, waterproofing, and high-altitude formulation, which are not obvious from the original patent. These adaptations enable the benzathine analogs to be used effectively in high-risk environments, providing a new and non-obvious solution.

Alternative Embodiments and Variations

Alternative embodiments may include adapting the device for use in extreme temperatures, integrating the wearable device with other vital sign monitoring systems, or developing new formulations for use in specific high-risk environments, such as desert or jungle settings.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical and medical device industries, particularly in the areas of emergency response, disaster relief, and extreme environment operations. The target market includes government agencies, non-governmental organizations, and private companies operating in these high-risk environments.

Field of Art

Pharmaceutical chemistry and medical device design, focusing on inflammatory disorder treatment and drug delivery systems, with expertise in pharmacological formulation and emergency medical technologies

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in pharmaceutical sciences or biomedical engineering, experienced in drug delivery mechanisms, medical device design, and understanding of inflammatory disorder treatments

Obviousness Rationale

A PHOSITA would recognize that the source patent's benzathine analog treatment for inflammatory disorders naturally invites adaptation to challenging environmental conditions. The core therapeutic mechanism remains unchanged, while the proposed variations represent predictable engineering solutions to extend the drug's usability. These modifications represent standard design approaches for medical technologies intended for diverse operational environments.

Obvious Combinations & Variations

Source Patent Element
Method for treating inflammatory disorders like sepsis and pneumonia
PTD Variation
Portable, waterproof device for emergency response administration
Obviousness Reasoning
Standard medical device design practice involves creating robust, portable delivery mechanisms for critical medications, representing a predictable engineering solution
Source Patent Element
Compound for treating infections from specific pathogens
PTD Variation
High-altitude formulation maintaining compound potency at reduced atmospheric pressure
Obviousness Reasoning
Pharmaceutical formulation techniques routinely involve adjusting drug stability for varying environmental conditions, which would be a known technique to a PHOSITA
Source Patent Element
Treatment method for inflammatory disorders
PTD Variation
Wearable device monitoring vital signs and dynamically adjusting compound dosage
Obviousness Reasoning
Adaptive drug delivery systems are a well-established approach in personalized medicine, representing an obvious extension of existing medical technology
Source Patent Element
Pharmaceutical compound for treating inflammatory conditions
PTD Variation
Composition with stabilizing agents for maintaining potency in extreme temperatures
Obviousness Reasoning
Temperature stabilization of pharmaceutical compounds is a standard pharmaceutical engineering challenge with well-known solution strategies
Source Patent Element
Method of administering compound for treating inflammatory disorders
PTD Variation
Kit with manual for administering in low-resource disaster relief settings
Obviousness Reasoning
Developing simplified administration protocols for challenging environments is a predictable design approach in emergency medical technologies
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857550, the proposed technical variations represent obvious extensions of the original inflammatory disorder treatment methodology, employing standard engineering and pharmaceutical design techniques that would be readily apparent to a person having ordinary skill in the art. The disclosed adaptations constitute prima facie obviousness under 35 U.S.C. § 103, as they represent predictable solutions to known technological challenges in medical device and pharmaceutical design.

Original Patent Information

Patent NumberUS 11,857,550
TitleBenzathine analogs
Assignee(s)UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, United States Government As Represented By The Department Of Veterans Affairs